番茄社区app

Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Menu
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your 番茄社区app member benefits, participate in College activities, and engage with your 番茄社区app colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your 番茄社区app member benefits, participate in College activities, and engage with your 番茄社区app colleagues. It's all here.

Become a Member
番茄社区app
Literature Selections

Debate May Continue Over Crystalloid Solutions and IVF Resuscitation

September 9, 2025

acs-store-journalperiodical.jpg

McIntyre L, Fergusson D, McArdle T, et al. . N Engl J Med 2025;393:660-670.

Crystalloid fluids, including normal saline and lactated Ringer鈥檚 solution, are among the most common interventions used in the treatment of hospitalized patients to reestablish hemodynamic stability, replace fluid losses, or maintain intravascular volume. Whether lactated Ringer鈥檚 solution is clinically superior to normal saline for routine intravenous administration of fluids has been the subject of debate.

Lauralyn McIntyre, from the University of Ottawa, and other members of the Canadian Critical Care Trials Group in Canada conducted an open-label, two-period, two-sequence, cross-sectional, cluster-randomized, crossover trial to compare outcomes in patients that had received lactated Ringer鈥檚 solution compared with normal saline.

Between August 2016 and March 2020, seven hospitals completed the required two 12-week periods of using either lactated Ringer鈥檚 solution only hospital-wide or normal saline solution only hospital-wide. Data on the primary outcome鈥攃omposite of death or readmission within 90 days after the index admission鈥攚ere available for 43,626 eligible patients. 

No serious adverse events were reported, and the researchers found no significant difference in patient outcomes.